India - English - Central Drugs Standard Control Organization

venus rem. - mannitol - 10ml

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - tablets - 200 milligram

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - 100/5 milligram

India - English - Central Drugs Standard Control Organization

l & v ph. - methylcobalamin,silymarin - od cap - 1500mcg,140mg - 10

India - English - Central Drugs Standard Control Organization

venus rem. - glycerin,mannitol - inf - 10,10;% - 100/300;ml

Singapore - English - HSA (Health Sciences Authority)

medtronic international, ltd. - general hospital - intended for locating and identifying cranial and peripheral motor and mixed motor-sensory nerves during surgery, including spinal cord and spinal nerve roots. the aps™electrode is an accessory intended for providing automatic periodic stimulation to nerves when used with the medtronic nerve monitoring systems.

Singapore - English - HSA (Health Sciences Authority)

medtronic international, ltd. - anaesthesiology - the nim 3.0 is intended for locating and identifying cranial and peripheral motor and mixed motor-sensory nerves during surgery, including spinal cord and spinal nerve roots.

Canada - English - Health Canada

bracco imaging canada - gadobenate dimeglumine - solution - 529mg - gadobenate dimeglumine 529mg - other diagnostic agents

Australia - English - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - posaconazole, quantity: 40 mg/ml - oral liquid, suspension - excipient ingredients: sodium benzoate; sodium citrate dihydrate; citric acid monohydrate; titanium dioxide; glycerol; xanthan gum; liquid glucose; peg-40 hydrogenated castor oil; purified water; peg-40 stearate; benzoic acid; glyceryl monostearate; methylcellulose; polysorbate 65; simethicone; sorbic acid; sulfuric acid; flavour - posaconazole is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older: ? invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy. ? fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy.,posaconazole is also indicated for the: ? treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole. ? prophylaxis of invasive fungal infections among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - posaconazole, quantity: 40 mg/ml - suspension - excipient ingredients: sodium benzoate; liquid glucose; titanium dioxide; polysorbate 80; xanthan gum; purified water; sodium citrate dihydrate; glycerol; simethicone; citric acid monohydrate; flavour - noxafil (posaconazole) is indicated for use in the treatment of the following invasive fungal infections in patients 13 years of age or older; invasive aspergillosis in patients intolerant of, or with disease that is refractory to, alternative therapy; fusariosis, zygomycosis, coccidioidomycosis, chromoblastomycosis, and mycetoma in patients intolerant of, or with disease that is refractory to, alternative therapy. noxafil is also indicated for the: treatment of oropharyngeal candidiasis in immunocompromised adults, including patients with disease that is refractory to itraconazole and fluconazole.prophylaxis of invasive fungal infections, among patients 13 years of age and older, who are at high risk of developing these infections, such as patients with prolonged neutropenia or haematopoietic stem cell transplant (hsct) recipients.